A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• RAF inhibitors like vemurafenib and dabrafenib are effective against BRAF(V600E)-mutant melanoma.
• Therapeutic resistance and lack of response limit the long-term efficacy of these treatments.

Purpose of the Study:

• To identify genetic factors contributing to resistance against RAF inhibitors in melanoma.
• To investigate the role of neurofibromin 1 (NF1) in mediating resistance to RAF and MEK inhibitors.

Main Methods:

• A pooled RNA interference screen was conducted to identify genes whose loss-of-function confers resistance to RAF inhibition.
• NF1's role in resistance was assessed by examining MAPK pathway activation and drug sensitivity in NF1-deficient cells.
• NF1 mutations were analyzed in melanoma cell lines and patient tumors resistant to RAF inhibitors.

Main Results:

• Loss of NF1 was identified as a major driver of resistance to RAF and MEK inhibitors.
• NF1 loss leads to sustained mitogen-activated protein kinase (MAPK) pathway activation, causing resistance.
• Cells lacking NF1 remained sensitive to an irreversible RAF inhibitor (AZ628) and an ERK inhibitor.
• NF1 mutations were found in intrinsically resistant melanoma cells and in tumors from patients who developed resistance to vemurafenib.

Conclusions:

• NF1 loss is a significant mechanism of acquired and intrinsic resistance to RAF/MEK-targeted therapies in BRAF-mutant melanoma.
• Targeting NF1 or utilizing alternative inhibitors may overcome resistance in these patients.
• Understanding NF1's role is crucial for developing strategies to improve melanoma treatment outcomes.